Drug Repurposing Based on Drug–Drug Interaction

Given the high risk and lengthy procedure of traditional drug development, drug repurposing is gaining more and more attention. Although many types of drug information have been used to repurpose drugs, drug–drug interaction data, which imply possible physiological effects or targets of drugs, remain unexploited. In this work, similarity of drug interaction was employed to infer similarity of the physiological effects or targets for the drugs. We collected 10 835 drug–drug interactions concerning 1074 drugs, and for 700 of them, drug similarity scores based on drug interaction profiles were computed and rendered using a drug association network with 589 nodes (drugs) and 2375 edges (drug similarity scores). The 589 drugs were clustered into 98 groups with Markov Clustering Algorithm, most of which were significantly correlated with certain drug functions. This indicates that the network can be used to infer the physiological effects of drugs. Furthermore, we evaluated the ability of this drug association network to predict drug targets. The results show that the method is effective for 317 of 561 drugs that have known targets. Comparison of this method with the structure‐based approach shows that they are complementary. In summary, this study demonstrates the feasibility of drug repurposing based on drug–drug interaction data.

[1]  Jie Li,et al.  Prediction of Polypharmacological Profiles of Drugs by the Integration of Chemical, Side Effect, and Therapeutic Space , 2013, J. Chem. Inf. Model..

[2]  Andreas Bender,et al.  The challenges involved in modeling toxicity data in silico: a review. , 2012, Current pharmaceutical design.

[3]  Organización Mundial de la Salud Guidelines for ATC classification and DDD assignment , 1996 .

[4]  Gary D. Bader,et al.  clusterMaker: a multi-algorithm clustering plugin for Cytoscape , 2011, BMC Bioinformatics.

[5]  M A Geyer,et al.  5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. , 2001, The Journal of pharmacology and experimental therapeutics.

[6]  David Cavalla,et al.  Predictive methods in drug repurposing: gold mine or just a bigger haystack? , 2013, Drug discovery today.

[7]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[8]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[9]  John M. Barnard,et al.  Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..

[10]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[11]  P. Bork,et al.  Large‐scale prediction of drug–target relationships , 2008, FEBS letters.

[12]  F. Schneider,et al.  Effects of ergotamine and dihydroergotamine on 5-hydroxytryptamine-2A receptors in the isolated rat aorta. , 1996, Pharmacology.

[13]  B. Roth,et al.  The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine’s actions? , 2005, Psychopharmacology.

[14]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[15]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[16]  Robert D Combes,et al.  Challenges for computational structure–activity modelling for predicting chemical toxicity: future improvements? , 2011, Expert opinion on drug metabolism & toxicology.

[17]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[18]  Trey Ideker,et al.  Cytoscape 2.8: new features for data integration and network visualization , 2010, Bioinform..